<DOC>
	<DOCNO>NCT02281292</DOCNO>
	<brief_summary>The purpose study evaluate initial safety intravitreal ( IVT ) LKA651 potential use alone combination Ranibizumab ophthalmic solution ( Lucentis® ) treatment Diabetic Macular Edema ( DME ) patient symptomatic disease .</brief_summary>
	<brief_title>A Study Safety Tolerability Intravitreal LKA651 Patients With Diabetic Macular Edema</brief_title>
	<detailed_description>This first-in-human study conduct 2 part . Part 1 ascend dose design ass safety , tolerability , pharmacodynamics pharmacokinetics various single IVT dose LKA651 48 subject diabetic macular edema . Subjects randomize receive active sham injection 3:1 ratio . A total 6 cohort ( 8 subject per cohort ) may enrol Part 1 . Each subject participate screening/eligibility period ( 60 day ) , treatment period ( single day ) , 84 day follow period . A total 11 visit take place , out-patient basis . An independent data monitoring committee ( DMC ) charter review cumulative safety data approve dose escalation cohort progression first-in-human trial . Part 2 double-masked design ass safety/tolerability , pharmacokinetics pharmacodynamics single IVT dose LKA651 co-administered Lucentis® . A total 3 cohort ( 8 subject per cohort ) may enrol Part 2 . Each subject participate screening/eligibility period ( 60 day ) , treatment period ( combination therapy , single day ) , 84 day follow period . A total 11 visit take place , out-patient basis . For LKA651 v sham injection , unmasked ophthalmologist permit assessment except injection ( inspection injection site immediately follow ) . All ocular assessment randomization conduct second ophthalmologist mask type injection ( active sham ) . The Lucentis injection ( Part 2 ) give open label patient follow either LKA651 sham injection .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Written informed consent must obtain . Type 1 type 2 diabetes actively manage physician hemoglobin A1C ≤ 12 % screening/eligibility . Negative pregnancy test result screening/eligibility preinjection treatment day . Diabetic macular edema ( DME ) center involvement least one eye , include focal diffuse DME . ETDRS letter score study eye 55 letter bad ( approximate Snellen equivalent 20/80 ) . The nonstudy eye ( fellow eye ) ≥ 60 letter well ( approximate Snellen equivalent 20/63 ) Day 1 predose . Safe withhold treatment study eye laser photocoagulation , intravitreal steroid injection , intravitreal vascular endothelial growth factor ( VEGF ) inhibitor ( Part 1 ) duration study . Other protocoldefined inclusion criterion may apply . Proliferative diabetic retinopathy study eye , exception tuft neovascularization le 1 disc area vitreous hemorrhage . Any progressive disease retina ( e.g . uveitis , rodcone dystrophy ) optic nerve ( e.g . glaucoma ) diabetic retinopathy . Any active infection involve ocular adnexa include infectious conjunctivitis , keratitis , scleritis , endophthalmitis , well idiopathic autoimmuneassociated uveitis either eye . Ocular disorder study eye may confound interpretation study result , include retinal vascular occlusion , retinal detachment , macular hole , choroidal neovascularization cause ( e.g. , AMD , ocular histoplasmosis , pathologic myopia ) . Cataract surgery study eye , YttriumAluminumGarnet ( YAG ) laser capsulotomy intraocular surgery within past 6 month precede Day 1 . Use systemic anticoagulant therapy study , e.g. , warfarin , heparin , etc . The use aspirin exclusion . Use investigational drug time enrollment , within 5 halflives enrollment , whichever longer ; longer require local regulation . Pregnant nursing ( lactate ) woman . Women childbearing potential , unless use highly effective method contraception dose study treatment . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>Intravitreal</keyword>
	<keyword>Retina</keyword>
	<keyword>Ophthalmology</keyword>
	<keyword>Lucentis</keyword>
	<keyword>OCT</keyword>
</DOC>